Terapia Génica en Enfermedad de Parkinson
PARKBA SAL
Universidad de Oviedo
Oviedo, EspañaUniversidad de Oviedo-ko ikertzaileekin lankidetzan egindako argitalpenak (6)
2020
-
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164
-
Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum
Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42
2019
-
Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease
Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910
2017
-
Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors
Frontiers in Pharmacology, Vol. 8, Núm. OCT
2016
-
Basic pharmacological and structural evidence for class A G-protein-coupled receptor heteromerization
Frontiers in Pharmacology, Vol. 7, Núm. MAR
-
Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay
Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 3, pp. 580-587